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Summary The protective effect of dual antiplatelet
therapy (DAPT) following acute coronary syndrome
is undisputed, but its duration is subject of debate.
Several studies show that prolonged therapy provides
a clinical benefit in patients following acute coronary
syndrome. The aim of this position paper authored
by Austrian experts is to outline the current evidence
and provide an overview of recent studies. It is also
intended to serve as a practical guide to identify those
patients who may benefit from prolonged DAPT.
Keywords P2Y12 inhibitor · Acute coronary syndrome ·
DAPT · Myocardial infarction · Ticagrelor
T. W. Weiss, MD, PhD, FESC () · K. Huber
3rd Medical Department of Cardiology and Intensive Care
Medicine, Wilhelminenhospital, Vienna, Austria
e-mail: thomas.weiss@meduniwien.ac.at
J. Aichinger
Internal Department 2 – Cardiology, Angiology and Internal
Intensive Medicine, Krankenhaus der Elisabethinen Linz,
Linz, Austria
W. S. Speidl
Clinical Department of Cardiology, University Clinic of
General Medicine II, Medical University of Vienna, Vienna,
Austria
N. Watzinger
Department of General Medicine, Landeskrankenhaus
Feldbach, Feldbach-Fürstenfeld Hospital Group, Feldbach,
Austria
R. Zweiker
Department of Cardiology, Medical University of Graz, Graz,
Austria
H. F. Alber
University Clinic of General Medicine III at the Medical
University of Innsbruck, Reha-Zentrum Münster, Tyrol and
Karl Landsteiner Institute for Interdisciplinary Research at
the Reha-Zentrum Münster, Münster/Tyrol, Austria
Introduction
Platelet activation and aggregation with consecutive
thrombus formation are key elements in the patho-
physiology of ischaemic cardiovascular events [1].
Oral antiplatelet therapy is therefore a central mea-
sure in the management of acute coronary syndrome
(ACS) and in the secondary prevention of cardiovas-
cular events.
International guidelines on the management of
non-ST elevation myocardial infarction (NSTEMI)
and ST elevation myocardial infarction (STEMI) rec-
ommend immediate therapy with acetylsalicylic acid
(ASA) and a P2Y12 inhibitor, both in patients who are
undergoing conservative treatment and in patients
undergoing interventional treatment. This dual an-
tiplatelet therapy (DAPT) is to be continued for at
least 12 months [2–6]. Tab. 1 provides an overview of
the current guidelines.
In certain situations, it is recommended to con-
sider the extended administration of DAPT beyond
the 12-month period (Fig. 1; [4–6]). According to the
2013 American College of Cardiology Foundation/
American Heart Association (ACCF/AHA) Guideline for
the Management of STEMI, therapy with a P2Y12 in-
hibitor beyond a year may be considered in high-risk
patients who receive a drug-eluting stent (DES; IIb C;
[5]). The 2014 ACCF/AHA Guideline for the Manage-
ment of Patients with Non-ST Elevation Acute Coronary
Syndromes recommends P2Y12 inhibitor therapy for at
least 12 months in patients after a percutaneous coro-
nary intervention (PCI) with stent implantation (I B)
[6]. The most recent guideline issued by the European
Society of Cardiology (ESC) for non-ST elevation ACS
state that a P2Y12 inhibitor therapy beyond one year
may be considered after carefully taking into consid-
eration the patient’s ischaemic and haemorrhagic risk
(IIb A) [4].
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Table 1 Current recommendations for dual antiplatelet therapy following anacute coronary syndrome
2015 ESC guidelines for the management of acute coronary syndromes in
patients presenting without persistent ST-segment elevation [4]
2014 ESC/EACTS Guidelines on myocardial revascularization [3]
Recommendations for platelet inhibition in non-ST-elevation acute coronary
syndromes
Recommendations for antithrombotic treatment in patients with STEMI
undergoing primary PCI
RC RL RC RL
Aspirin is recommended for all patients without
contraindications at an initial oral loading dosed of
150–300 mg (in aspirin-naive patients) and a maintenance
dose of 75–100 mg/day long-term regardless of treatment
strategy
I A ASA is recommended for all patients without
contraindications at an initial oral loading dose of
150–300 mg (or 80–150 mg i. v.) and at a maintenance
dose of 75–100 mg daily long-term regardless of
treatment strategy
I A
A P2Y12 inhibitor is recommended, in addition to aspirin,
for 12 months unless there are contraindications such as
excessive risk of bleeds
I A A P2Y12 inhibitor is recommended in addition to ASA and
maintained over 12 months unless there are
contraindications such as excessive risk of bleeding.
Options are:
I A
– Ticagrelor (180 mg loading dose, 90 mg twice daily) is
recommended, in the absence of contraindicationsa, for
all patients at moderate-to-high risk of ischaemic
events (e. g. elevated cardiac troponins), regardless of
initial treatment strategy and including those pretreated
with clopidogrel (which should be discontinued when
ticagrelor is started)
I B – Ticagrelor (180 mg loading dose, 90 mg twice daily) if
no contraindication
I B
– Prasugrel (60 mg loading dose, 10 mg daily dose) is
recommended in patients who are proceeding to PCI if
no contraindicationa
I B – Prasugrel (60 mg loading dose, 10 mg daily dose) if no
contraindication
I B
– Clopidogrel (300–600 mg loading dose, 75 mg daily
dose) is recommended for patients who cannot receive
ticagrelor or prasugrel or who require oral
anticoagulation
I B – Clopidogrel (600 mg loading dose, 75 mg daily dose),
only when prasugrel or ticagrelor are not available or
are contraindicated
I B
It is not recommended to administer prasugrel in patients
in whom coronary anatomy is not known
III B It is recommended to give P2Y12 inhibitors at the time of
first medical contact
I B
P2Y12 inhibitor administration for a shorter duration of
3–6 months after DES implantation may be considered in
patients deemed at high bleeding risk
IIb A
P2Y12 inhibitor administration in addition to aspirin beyond
1 year may be considered after careful assessment of the
ischaemic and bleeding risks of the patient
IIb A
RC Recommendation Class, RL Recommendation Level
aContraindications for ticagrelor: previous intracranial haemorrhage or ongoing bleeds. Contraindications for prasugrel: previous intracranial haemorrhage,
previous ischaemic stroke or transient ischaemic attack or ongoing bleeds; prasugrel is generally not recommended for patients ≥ 75 years of age or with
a bodyweight < 60 kg
Rationale for prolonged DAPT
The rationale for prolonged DAPT is the fact that the
ischaemic risk of patients following myocardial in-
farction remains high beyond the first year [7, 8]. This
is shown, for example, by Swedish record data from
more than 100,000 patients who were hospitalised
with myocardial infarction. The risk of these patients
suffering a severe cardiovascular event (nonfatal my-
ocardial infarction, nonfatal stroke or cardiovascular
death) in the first year after the acute event was ~ 18%.
Event-free patients in the first year still had an ap-
proximate 20% risk of an event in the following three
years. The probability of suffering such an event was
linked to the number of cardiovascular risk factors.
Older age, stroke, diabetes, heart failure and no index
revascularisation were independently associated with
an increased risk of ischaemic events or mortality
[8]. The prolonged increased risk in stable patients
following an ACS in comparison with patients with
stable coronary artery disease without ACS was also
demonstrated in British record data, in which the
5-year risk of infarction or sudden cardiac death was
approximately double in patients with STEMI, and
almost triple in patients with NSTEMI (Fig. 2; [9]).
The long-term increased risk of recurrence is based
on the fact that the treatment of the acute event does
not constitute causal therapy of atherosclerosis itself,
which is a progressive, systemic disease that is not
limited to a culprit lesion. It has been shown that only
half of recurrent ischaemic cardiac events in patients
who have undergone a successful percutaneous coro-
nary intervention (PCI) in relation to ACS are caused
by the culprit lesion, while the other half are caused
by non-culprit or de novo lesions [10]. (For further
literature on the subject of plaque vulnerability, see
[11]). Therefore, intensive secondary prevention with
rigorous control of all individual risk factors (blood
pressure, blood sugar, lipids) is crucial for the patient’s
prognosis.
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Fig. 1 Recent changes in recommendationsof prolongeddual antiplatelet therapy in international guidelines.ESCEuropeanSo-
cietyofCardiology,STE-ACSST-SegmentElevationAcuteCoronarySyndrome,ACSAcuteCoronarySyndrome,NSTE-ACSNon-
ST-SegmentElevationAcuteCoronarySyndrome,DAPTDual Antiplatelet Therapy,BMSBareMetal Stent,DESDrugEluting
Stent,STEMIST-SegmentElevationMyocardial Infarction,PCIPercutaneousCoronary Intervention,ASAAcetylicSalicylicAcid,
ACCF AmericanCollegeofCardiologyFoundation,AHAAmericanHeartAssociation
Fig. 2 Kaplan–Meier risk (nonfatalMIor coronarydeath)
for stable anginapatients (n=45,645), STEMI (n=4,700)
andNSTEMI (n=6,818). For ACSpatients, follow-upstarted
6monthsafter index event. Mean follow-up timewas4.4 years.
Adapted from [9]CHDcoronaryheart disease,MImyocardial
infarction,NSTEMInon-ST-elevationmyocardial infarction,
STEMIST-elevationmyocardial infarction
Risk and benefit of prolonged DAPT
Prolonged DAPT not only has the potential to reduce
the stent thrombosis risk, but is also associated with
a reduced risk of recurrent infarctions [12–14].
Although the Clopidogrel for High Atherothrom-
botic Risk and Ischemic Stabilization, Management,
and Avoidance (CHARISMA) study on prolonged
DAPT with clopidogrel/ASA over 28 months did not
show any benefit of prolonged DAPT with regard to
cardiovascular risk for the total patient cohort [15],
a retrospective subgroup analysis revealed that the
prolonged DAPT significantly reduced the risk of ma-
jor cardiovascular events in the secondary prevention
setting after myocardial infarction [12].
In the Dual Antiplatelet Therapy (DAPT) study,
prolonged DAPT over 30 months was compared with
DAPT over 12 months. This study included patients
with stable coronary artery disease or acute coronary
syndrome, provided they had received at least one
stent. A subgroup analysis showed that in patients
both with and without myocardial infarction, the ex-
tended DAPT lowered the risk of stent thrombosis.
In patients with myocardial infarction, the extended
DAPT also reduced the risk of major cardiovascular
events (cardiovascular death, myocardial infarction,
stroke) [13].
In addition to these studies, the Platelet Inhibition
and Patient Outcomes (PLATO) study points towards
a benefit of prolonged DAPT. More intensive platelet
inhibition with ticagrelor 90 mg twice daily reduced
the risk of cardiovascular morbidity and mortality in
comparison with clopidogrel 75 mg once daily not
only in the early phase after the acute event, but also
continuously and incrementally in the more stable
phase until the end of follow-up up to 12 months [16].
Extended DAPT with ticagrelor 60 mg twice daily
(PEGASUS-TIMI-54 study)
The first prospective study to examine the effect of
prolonged DAPT in post-MI patients was the Preven-
tion of Cardiovascular Events in Patients with Prior
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Fig. 3 Patientswere ran-
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Heart Attack Using Ticagrelor Compared to Placebo on
a Background of Aspirin-Thrombolysis in Myocardial
Infarction 54 (PEGASUS-TIMI-54) study published in
2015 [17].
Study population, study medication, endpoints
This double-blind, placebo-controlled study involved
21,162 high-risk patients with a history of myocar-
dial infarction and at least one other cardiovas-
cular risk factor (diabetes mellitus, re-infarction,
aged ≥ 65 years, multivessel coronary artery disease,
chronic non-end-stage renal dysfunction). These pa-
tients were included in the study one to three years
after the acute event [17, 18]. In the first year after
the myocardial infarction, the DAPT treatment was
given independently of the PEGASUS-TIMI-54 trial.
As the patients were included between October 2010
and April 2013 and the qualifying myocardial infarc-
tion must have happened one to three years before
that time, the majority of the patients received clopi-
dogrel in the first year following their ACS. At that
time, prasugrel had only recently been launched on
the market and ticagrelor only became available for
general clinical use during the course of the PEGASUS
trial.
Key exclusion criteria included patients with a his-
tory of ischaemic stroke, recent haemorrhage or oral
anticoagulant therapy.
The patients were randomised in a ratio of 1:1:1 to
receive ticagrelor 90 mg twice daily, ticagrelor 60 mg
twice daily or placebo. Patients received ASA at a low
dosage (maintenance dose ≤ 150 mg) and were fol-
lowed up for a period of 33 months. The primary effi-
cacy endpoint was the combination of cardiovascular
death, myocardial infarction or stroke. The primary
safety endpoint was major haemorrhage as classified
by the Thrombolysis in Myocardial Infarction (TIMI)
criteria (fatal haemorrhage, intracranial haemorrhage,
a reduction in haemoglobin ≥ 5 g/dl or a reduction in
haematocrit ≥ 15%) [19].
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Fig. 5 Cumulative event
ratesof TIMImajor bleeding
at 3 yearswere1.06% in
theplacebogroup, 2.6% in
the ticagrelor 90mg twice
daily groupand2.3% in
the ticagrelor 60mg twice
daily group. The3yearKa-









At both dosages, ticagrelor significantly reduced the
risk of the primary efficacy endpoint in comparison
with placebo (Kaplan–Meier rates at year 3 – ticagrelor
90 mg twice daily: 7.85%; ticagrelor 60 mg twice daily:
7.77%; placebo: 9.04%; Fig. 3). The hazard ratio
(HR) for ticagrelor 90 mg twice daily versus placebo
was 0.85 (95% confidence interval [CI]: 0.75–0.96; p =
0.008) and the HR for ticagrelor 60 mg twice daily ver-
sus placebo was 0.84 (95% CI: 0.74–0.95; p = 0.004).
The comparability of the efficacy and safety of tica-
grelor 90 mg twice daily and ticagrelor 60 mg twice
daily have been reflected in the approval of ticagrelor
60 mg twice daily for prolonged DAPT by the Euro-
pean Medicines Agency (EMA) on 19 February 2016.
Therefore, only the data for the ticagrelor dosage that
is clinically relevant for prolonged DAPT, 60 mg twice
daily, will be quoted in the following sections.
The exploratory analysis showed that ticagrelor
60 mg twice daily versus placebo resulted in a signif-
icant reduction in the rate of myocardial infarction,
a reduced rate of stroke and comparable cardiovas-
cular mortality. Fig. 4 provides an overview of the
evaluation of the individual efficacy endpoints of the
primary combined endpoint.
For every 10,000 patients who start prolonged
DAPT with ticagrelor 60 mg twice daily (intention-
to-treat analysis), 42 primary endpoint events can be
prevented every year.
Safety data
Over a period of three years, the frequency of TIMI
major bleedings was significantly higher with tica-
grelor 60 mg twice daily than with placebo (2.30% vs.
1.06%; p = 0.001), while the rates of intracranial or fa-
tal haemorrhage were comparable (0.71% vs. 0.60%).
Fig. 5 shows the cumulative bleeding event rates at
3 years.
Over a three-year period, dyspnoea was more fre-
quent with ticagrelor 60 mg twice daily in comparison
with placebo (15.84% vs. 6.38%; p < 0.001). This side
effect was mostly mild or moderate and in many cases
only temporary. Hence, the discontinuation rates due
to dyspnoea were much lower at only 4.55% in the
ticagrelor 60 mg arm (placebo: 0.79%; p < 0.001).
Discontinuation of therapy due to dyspnoea occurred
soon after initiation of therapy.
Renal events and bradyarrhythmias occurred in
the treatment groups at similar frequencies. Severe
episodes of gout were documented more frequently
with ticagrelor than with placebo.
Further analyses
● Patientswho started treatmentwith ticagrelor 60mg
twice daily within a short time (≤ 30 days of ASA
monotherapy) after the end of the initial DAPT
received a greater benefit than patients in whom
DAPTwas stopped for a longer periodof time (Fig. 6;
[20]).
● The rate of haemorrhage resulting in irreversible
damage or death was < 1% in all groups over the
three-year period, without any statistically signifi-
cant difference between ticagrelor and the placebo
group.
● The analysis of the primary efficacy endpoint in
combination with the primary safety endpoint of
TIMI major bleedings showed no significant differ-
ence between ticagrelor and placebo. However, in
terms of the combined benefit/safety analysis of
ischaemic endpoints and bleeding events with irre-
versible damage (i. e. intracranial and fatal haemor-
rhage), prolongedDAPT with ticagrelor 60 mg twice
daily demonstrated a benefit in comparison with
placebo [21].
● Already in the first 12 months after an ACS, tica-
grelor proved to be particularly beneficial in pa-
tients with stage III kidney disease as shown in the
PLATO study [16]. This tendency can also be ob-
served in PEGASUS [22].
454 Expert position paper on prolonged dual antiplatelet therapy in secondary prevention following myocardial. . . K
review article
Fig. 6 aTimelineofpatientsenrolled intrial. After thequalifyingACSpatientsweretreatedwithDAPTindependentof thestudy. After
DAPTwithdrawal patientswere treatedwithASSmonotherapyuntil randomization to ticagrelor orplacebo.bAnalysisof 3-year rate
of efficacyendpoint (CVdeath, stroke,MI) according to time from lastP2Y12inhibitor to randomization (=ASAmonotherapyphase).
days: ≤30, >30–360, >360. Data is shown for ticagrelor 60mg twicedaily vsplacebo.Adapted from [20]. ASAacetylsalicylic acid,
ACSacute coronary syndrome,DAPT dual antiplatelet therapy,HRhazard ratio,RRR relative risk reduction
Recommendation for the use of prolonged DAPT
with ticagrelor 60 mg twice daily/ASA 100 mg in
patients following myocardial infarction
In addition to optimum control of cardiovascular risk
factors (lipids, blood sugar and blood pressure, smok-
ing cessation, weight control), the following procedure
can be recommended for prolonged DAPT:
● Patient selection: The prerequisite for the indica-
tion of prolonged DAPT is the individual evalu-
ation of the ischaemic and bleeding risk. Pro-
longed DAPT is recommended accordingly in pa-
tients demonstrating one of the following charac-
teristics: Stent thrombosis, re-infarction, complex
coronary anatomy, complex intervention, overt di-
abetes mellitus, peripheral arterial disease (PAD),
non-end stage chronic kidney disease (especially
stage III) (see Fig. 7). Regardless of cardiovascular
risk, the following patients should rather not receive
prolonged DAPT: Patients with a history of haemor-
rhage or at high risk of haemorrhage (e. g. a CRU-
SADE score > 40) [23], a history of TIA or stroke,
patients on oral anticoagulant therapy or under
continuous treatment with nonsteroidal anti-in-
flammatory drugs (NSAIDs), frail patients, patients
with malignancies and patients with stage IV–V
chronic renal disease.
● Indication:
1. In an acute event by the treating interventional
cardiologist: The main indication for prolonged
DAPT with ticagrelor 60 mg twice daily should be
determined at the time of the acute event, doc-
umented in the discharge letter and explanatory
argument. This is an easy timepoint at which
the complexity of the intervention and of the
coronary anatomy can be assessed.
2. By the rehabilitation physician: Inpatient/outpa-
tient rehabilitation offers a good opportunity to
inform patients about the value of prolonged
DAPT if the decision was not made at the acute
hospital, and the initial tolerability of DAPT can
be assessed under medical supervision.
3. Within one year from the acute event, e. g. by
a resident specialist for internal medicine: Before
the end of the standard 12-month DAPT, the
initial indication for prolonged DAPT with tica-
grelor 60 mg twice daily should be reassessed
on the basis of the tolerability of the now almost
Fig. 7 Careful evaluationof thecardiovascular risk factorsand
bleeding risk factors shoulddetermine the recommendationof
DAPTdurationatthetimeofdischargefromthehospitalafterMI.
OACoral anticoagulation,PADperipheral arterydisease
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one-year DAPT (no clinically significant haem-
orrhage) and the persistently high ischaemic
risk. If indicated, the prolonged DAPT should be
continuously prescribed.
● Notes for primary care providers:
– When using ticagrelor in the first year after my-
ocardial infarction, the recommended dose is
90 mg twice daily [2–6]. The corresponding
dose for prasugrel is 10 mg once daily (except
in elderly and low weight patients in whom
a dose reduction to 5 mg is recommended) and
for clopidogrel 75 mg once daily in this first
year. Prolonged DAPT with ticagrelor has been
approved at a dose of 60 mg twice daily.
– At 12 months following ACS, ticagrelor 90 mg
twice daily, prasugrel 10 mg once daily or clopi-
dogrel 75 mg once daily can be switched directly
to ticagrelor 60 mg twice daily (with no loading
dose). As far as possible, DAPT with ticagrelor
60 mg twice daily should be continued without
interruption following the 12-month DAPT after
ACS.
– Ticagrelor 60 mg twice daily is permitted as part
of prolonged DAPT provided that therapy is ini-
tiated within two years after the acute event or
within one year after the end of a preceding
course of DAPT.
– Ticagrelor 60 mg twice daily is permitted for
long-term therapy; study data over a period of
three years is available.
Acknowledgements Medical writing support was provided
by AstraZeneca.
Conflict of interest The following authors declare that they
have served as a consultant, received a speaker fee, or re-
ceived financial support for performing a research project
of industrial companies: T. W. Weiss: AstraZeneca, Dai-
ichi Sankyo, Eli-Lilly; J. Aichinger: AstraZeneca, Daiichi
Sankyo, Eli-Lilly; K. Huber: AstraZeneca, Daiichi Sankyo,
Eli-Lilly, Merck Sharp Dohme, the Medicines Company;
W. S. Speidl: AstraZeneca; N. Watzinger: AstraZeneca, Merck
Sharp Dohme; R. Zweiker: AstraZeneca, Daiichi Sankyo, Eli-
Lilly, Merck Sharp Dohme; H. F. Alber: AstraZeneca, Dai-
ichi Sankyo, Eli-Lilly, Merck Sharp Dohme, the Medicines
Company.
Open Access This article is distributed under the terms of
the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which per-
mits unrestricted use, distribution, and reproduction in any
medium, provided you give appropriate credit to the origi-
nal author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made.
References
1. Kapoor JR. Platelet activation and atherothrombosis. N
Engl JMed. 2008;358:1638,authorreply–9.
2. Steg PG, James SK, Atar D, et al. ESC Guidelines for the
management of acute myocardial infarction in patients
presenting with ST-segment elevation. Eur Heart J.
2012;33:2569–619.
3. Windecker S, Kolh P, Alfonso F, et al. ESC/EACTS
Guidelines on myocardial revascularization: The Task
Force on Myocardial Revascularization of the European
Society of Cardiology (ESC) and the European Association
for Cardio-Thoracic Surgery (EACTS)Developed with the
special contribution of the European Association of
Percutaneous Cardiovascular Interventions (EAPCI). Eur
HeartJ.2014;2014(35):2541–619.
4. Roffi M, Patrono C, Collet JP, et al. ESC guidelines for
themanagement of acute coronary syndromes in patients
presenting without persistent ST-segment elevation: task
force for the management of acute coronary syndromes
in patients presenting without persistent ST-segment
elevation of the European Society of Cardiology (ESC). Eur
HeartJ.2015;2016(37):267–315.
5. O’GaraPT,KushnerFG,AscheimDD,etal. 2013ACCF/AHA
guideline for themanagement of ST-elevationmyocardial
infarction: a report of the american college of cardiology
foundation/american heart association task force on
practiceguidelines. Circulation. 2013;127:e362–e425.
6. Amsterdam EA, Wenger NK, Brindis RG, et al. AHA/ACC
guideline for the management of patients with non-ST-
elevationacutecoronarysyndromes: executivesummary: a
reportoftheamericancollegeofcardiology/americanheart
association task force on practice guidelines. Circulation.
2014;2014(130):2354–94.
7. Fox KA, Carruthers KF, Dunbar DR, et al. Underestimated
and under-recognized: the late consequences of acute




patients: nationwide real world data demonstrate the
importance of a long-term perspective. Eur Heart J.
2015;36:1163–70.
9. Rapsomaniki E, Shah A, Perel P, et al. Prognostic models
for stable coronary artery disease based on electronic
health record cohort of 102 023 patients. Eur Heart J.
2014;35:844–52.
10. Stone GW, Maehara A, Lansky AJ, et al. A prospective
natural-history study of coronary atherosclerosis. NEngl J
Med. 2011;364:226–35.
11. Arbab-Zadeh A, Fuster V. The myth of the “vulnerable
plaque”: transitioning fromafocuson individual lesions to
atheroscleroticdisease burden for coronary artery disease
riskassessment. JAmCollCardiol. 2015;65:846–55.
12. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior
myocardial infarction, stroke, or symptomatic peripheral
arterial disease in the CHARISMA trial. J Am Coll Cardiol.
2007;49:1982–8.
13. Yeh RW, Kereiakes DJ, Steg PG, et al. Benefits and risks of
extended duration dual antiplatelet therapy after PCI in
patientswithandwithoutacutemyocardial infarction. JAm
CollCardiol. 2015;65:2211–21.
14. BonacaMP, Scirica BM, Braunwald E, et al. New ischemic
strokeandoutcomeswithvorapaxarversusplacebo: results
from the TRA 2 degrees P-TIMI 50 trial. J AmColl Cardiol.
2014;64:2318–26.
15. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin
versusaspirinalonefor thepreventionofatherothrombotic
events. NEngl JMed. 2006;354:1706–17.
456 Expert position paper on prolonged dual antiplatelet therapy in secondary prevention following myocardial. . . K
review article
16. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus
clopidogrel in patients with acute coronary syndromes. N
Engl JMed. 2009;361:1045–57.
17. Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of
ticagrelor in patients with priormyocardial infarction. N
Engl JMed. 2015;372:1791–800.
18. Bonaca MP, Bhatt DL, Braunwald E, et al. Design and
rationale for the Prevention of Cardiovascular Events in
PatientsWithPriorHeartAttackUsingTicagrelorCompared
to Placebo on a Background of Aspirin-Thrombolysis in
Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. Am
HeartJ.2014;167(44):437,e5.
19. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding
definitions for cardiovascular clinical trials: a consensus
report fromthe Bleeding Academic ResearchConsortium.
Circulation. 2011;123:2736–47.
20. Bonaca MP, Bhatt DL, Steg PG, et al. Ischaemic risk
and efficacy of ticagrelor in relation to time from P2Y12
inhibitor withdrawal in patients with prior myocardial
infarction: insights from PEGASUS-TIMI 54. Eur Heart J.
2015;37(14):1133–42.
21. Magnani G, Bonaca MP, Sabatine MS. Editorial on PE-
GASUS–TIMI 54. Eur Heart J Cardiovasc Pharmacother.
2015;1:217–9.
22. Magnani G, Storey RF, Steg G, et al. Efficacy and
safety of ticagrelor for long-term secondary prevention
of atherothrombotic events in relation to renal function:
insights from the PEGASUS-TIMI 54 trial. Eur Heart J.
2016;37:400–8.
23. http://www.crusadebleedingscore.org/. Accessed May
2016.
K Expert position paper on prolonged dual antiplatelet therapy in secondary prevention following myocardial. . . 457
